Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Free Cash Flow (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Free Cash Flow for 4 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 25.02% to -$2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.9 million, a 61.93% decrease, with the full-year FY2024 number at -$5.8 million, down 25.03% from a year prior.
  • Free Cash Flow was -$2.1 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$1.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$97552.0 in Q4 2022 to a low of -$3.7 million in Q3 2023.
  • A 4-year average of -$1.2 million and a median of -$1.3 million in 2024 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 54.67% in 2024; the steepest drop was 1271.26% in 2024.
  • 60 Degrees Pharmaceuticals' Free Cash Flow stood at -$97552.0 in 2022, then dropped by 22.47% to -$119468.0 in 2023, then plummeted by 1271.26% to -$1.6 million in 2024, then decreased by 29.35% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Free Cash Flow are -$2.1 million (Q3 2025), -$1.5 million (Q2 2025), and -$1.6 million (Q1 2025).